Literature DB >> 8648701

Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

P J Klasse1, J P Moore.   

Abstract

Primary isolates (PI) of human immunodeficiency virus type 1 (HIV-1) are considerably less sensitive than T-cell line-adapted strains to neutralization by soluble CD4 and by most cross-reactive monoclonal antibodies to the viral envelope (Env) glycoprotein, as well as by postinfection and postvaccination sera (J. P. Moore and D. D. Ho, AIDS 9 [suppl. A]:5117-5136, 1995). We developed a quantitative model to explain the neutralization resistance of PI. The factors incorporated into the model are the dissociation constants for the binding of the neutralizing agent to native Env oligomers, the number of outer Env molecules on the viral surface (which decreases by shedding), and the minimum number of Env molecules required for attachment and fusion. We conclude that modest differences in all these factors can, when combined, explain a relative neutralization resistance of PI versus T-cell line-adapted strains that sometimes amounts to several orders of magnitude. The hypothesis that neutralization of HIV is due to the reduction below a minimum number of the Env molecules on a virion available for attachment and fusion is at odds with single- and few-hit neutralization theories. Our analysis of these ideas favors the hypothesis that neutralization of HIV is instead a competitive blocking of interactions with cellular factors, including adsorption receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648701      PMCID: PMC190242     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus.

Authors:  R DULBECCO; M VOGT; A G STRICKLAND
Journal:  Virology       Date:  1956-04       Impact factor: 3.616

2.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.

Authors:  J P Moore; Q J Sattentau; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

3.  Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization.

Authors:  P J Klasse; J A McKeating
Journal:  AIDS Res Hum Retroviruses       Date:  1993-07       Impact factor: 2.205

4.  gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment.

Authors:  L Marcon; J Sodroski
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.

Authors:  D C Bou-Habib; G Roderiquez; T Oravecz; P W Berman; P Lusso; M A Norcross
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

6.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

Authors:  N Sullivan; Y Sun; J Li; W Hofmann; J Sodroski
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.

Authors:  A Ashkenazi; D H Smith; S A Marsters; L Riddle; T J Gregory; D D Ho; D J Capon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

8.  Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.

Authors:  M Groenink; J P Moore; S Broersen; H Schuitemaker
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

9.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  39 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Regulation of virus neutralization and the persistent fraction by TRIM21.

Authors:  W A McEwan; F Hauler; C R Williams; S R Bidgood; D L Mallery; R A Crowther; L C James
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

3.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

4.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Dense Array of Spikes on HIV-1 Virion Particles.

Authors:  Armando Stano; Daniel P Leaman; Arthur S Kim; Lei Zhang; Ludovic Autin; Jidnyasa Ingale; Syna K Gift; Jared Truong; Richard T Wyatt; Arthur J Olson; Michael B Zwick
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

6.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.

Authors:  Rajesh P Ringe; Pavel Pugach; Christopher A Cottrell; Celia C LaBranche; Gemma E Seabright; Thomas J Ketas; Gabriel Ozorowski; Sonu Kumar; Anna Schorcht; Marit J van Gils; Max Crispin; David C Montefiori; Ian A Wilson; Andrew B Ward; Rogier W Sanders; P J Klasse; John P Moore
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

7.  Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Authors:  Per Johan Klasse
Journal:  Virology       Date:  2007-09-07       Impact factor: 3.616

8.  Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping Virometry.

Authors:  Michael C DeSantis; Jin H Kim; Hanna Song; Per Johan Klasse; Wei Cheng
Journal:  J Biol Chem       Date:  2016-04-25       Impact factor: 5.157

9.  The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection.

Authors:  Theodore C Pierson; Qing Xu; Steevenson Nelson; Theodore Oliphant; Grant E Nybakken; Daved H Fremont; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-04-19       Impact factor: 21.023

10.  Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.

Authors:  P J Klasse
Journal:  Adv Biol       Date:  2014-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.